Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BAY 43-9006 (sorafenib) in patients with advanced cholangiocarcinoma
2006-001014-32Phase 2Completed
- Sponsor
- AOU Policlinico di Modena
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in cholangiocarcinoma (CCA) and biliary neoplasm, sponsored by AOU Policlinico di Modena. Primary endpoint: Disease control at 12 weeks. Started Jul 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
cholangiocarcinoma (CCA)biliary neoplasm
Beyond the preview
Go deeper on 2006-001014-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001014-32.